Helus Pharma Raises $50M in Underwritten Share Offering
Event summary
- Helus Pharma closed a $50M underwritten offering of 10.3M common shares at $4.85 per share.
- Proceeds will fund Phase 3 trials for HLP003 (major depressive disorder) and development of HLP004/HLP005.
- Cantor and Barclays acted as joint bookrunners, with Bloom Burton and Lucid Capital as lead managers.
- Offering conducted under a base shelf prospectus filed in Canada and the U.S. in December 2025.
The big picture
Helus Pharma's $50M raise underscores investor confidence in novel serotonergic agonists amid growing demand for depression and anxiety treatments. The capital infusion positions the company to accelerate Phase 3 trials, but success hinges on differentiating HLP003 in a competitive landscape where regulatory approval remains the ultimate validation.
What we're watching
- Clinical Milestones
- Whether Phase 3 APPROACH data for HLP003 in Q4 2026 meets regulatory expectations.
- Capital Deployment
- How efficiently Helus Pharma allocates proceeds across its pipeline and corporate needs.
- Market Positioning
- The pace at which competitors advance serotonergic agonists for mental health disorders.
Related topics